- The U.S. medical business unit of distributor Henry Schein (NASDAQ:HSIC), Henry Schein Medical, signs on to sell Cepheid's (NASDAQ:CPHD) GeneXpert System on a non-exclusive basis. It will promote the product and its menu of 17 tests to non-acute care laboratories in the U.S. (non-hospital labs).
- The total potential market consists of more than 10,000 moderately complex non-hospital laboratories and more than 100,000 CLIA-waived physician office labs (once the GeneXpert Omni is available in ~one year).